Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 6/20 | 0.41 |
| ▸ | FEN1 | P39748 | 6/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DNASE1 | P24855 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120564 | 0.85 | ERCC1 (0.44) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5129277 | 0.83 | SMN1; SMN2 (0.46) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5254746 | 0.83 | SMN1; SMN2 (0.45) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5122895 | 0.80 | SMN1; SMN2 (0.47) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5252286 | 0.79 | HPGD (0.55) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5128865 | 0.79 | SMN1; SMN2 (0.45) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5119262 | 0.79 | KMT2A (0.53) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5251255 | 0.79 | HPGD (0.47) | SMN1; SMN2LMNANPC1KDM4ERAB9A | |
| SCHEMBL5114712 | 0.79 | POLB (0.53) | ERCC1FEN1ERCC4SMN1; SMN2LMNA | |
| SCHEMBL5115087 | 0.79 | SMN1; SMN2 (0.53) | ERCC1FEN1ERCC4SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | ERCC1 1789/4885FEN1 582/4885ERCC4 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.